The Clinical and Economic Impact of Penicillin Allergy

青霉素过敏的临床和经济影响

• 批准号: 10408342
• 负责人: Kimberly Gold Blumenthal
• 金额: $ 9.54万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-22 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10408342
• 关键词: Allergic; Allergic Reaction; Anaphylaxis; Antibiotics; Antimicrobial Resistance; Centers for Disease Control and Prevention (U.S.); Clinical; Cost Effectiveness Analysis; Databases; Drug Hypersensitivity; Economics; Environment; Epidemiologist; Epidemiology; Evaluation; Frequencies; Funding; General Hospitals; Healthcare; Hypersensitivity; Hypersensitivity skin testing; Immune; Immunologist; Immunology; Internal Medicine; International; K-Series Research Career Programs; Knowledge; Massachusetts; Master of Science; Mediating; Medicine; Mentors; Mentorship; Methods; Monobactams; Outcome; Patient Self-Report; Patient-Focused Outcomes; Patients; Penicillin Allergy; Penicillins; Population; Positioning Attribute; Public Health; Public Health Schools; Reaction; Reporting; Research; Research Proposals; Research Training; Resources; Science; Training; Training Activity; United States National Institutes of Health; Universities; adverse drug reaction; beta-Lactams; care costs; career; clinical epidemiology; cost effectiveness; economic impact; genetic linkage analysis; healthcare-associated infections; medical schools; models and simulation; professor; programs; simulation; skills

PROJECT SUMMARY Candidate. Kimberly G. Blumenthal, MD, MSc is an allergist/immunologist at Massachusetts General Hospital (MGH) and an Assistant Professor of Medicine at Harvard Medical School. After studying economics at Columbia University, she received her MD from Yale University. Dr. Blumenthal completed Internal Medicine and Allergy/Immunology training at MGH, and a Masters of Science at the Harvard T.H. Chan School of Public Health. Dr. Blumenthal aims to be an international leader in drug allergy epidemiology and simulation research. Mentorship, Training Activities, and Environment. Dr. Blumenthal was mentored by Rochelle P. Walensky, MD, MPH until her departure in January 2021 to direct the Centers for Disease Control and Prevention. Dr. Walensky was NIH-funded from 2006-2021; she had successfully transitioned >5 fellows to independent R01- funded research careers. Dr. Blumenthal’s current mentor is Dr. Carlos Camargo, an internationally recognized expert in anaphylaxis and NIH-funded epidemiologist. Dr. Blumenthal has acquired new skills, including linkage and analysis of large databases, resource utilization analysis, and simulation modeling and cost-effectiveness analysis. The collaborative opportunities, intellectual environment, and resources available to Dr. Blumenthal are outstanding and provide her with a clear path to independence. Research. Penicillin (PCN) allergy is reported by over 10% of the U.S. population, though a self-reported PCN allergy infrequently reflects an inability to tolerate PCNs and other beta-lactam antibiotics. Unnecessary use of beta- lactam alternative antibiotics leads to more antimicrobial resistance and healthcare-associated infections. Beta-lactam antibiotics are the most common cause of drug hypersensitivity reactions, the immune-mediated subset of adverse drug reactions. PCN allergy evaluation can distinguish between patients with and without true PCN hypersensitivity. The K01 scientific program, The Clinical and Economic Impact of Penicillin Allergy, has three specific aims that align with national priorities including curbing antimicrobial resistance: 1) To assess the clinical and economic impact of reported PCN allergy. 2) To determine the frequency, predictors, and healthcare resource impact of beta-lactam antibiotics. 3) To project the clinical outcomes, budgetary impact, and cost-effectiveness of PCN allergy evaluation. Completion of this research proposal and training plan will position Dr. Blumenthal for an independent research career as a drug allergy expert with methods skills in clinical epidemiology and decision science.

项目总结 候选人。金伯利·G·布鲁门撒尔，医学博士，硕士，马萨诸塞州综合医院的过敏学家/免疫学家 他是哈佛大学医学院的医学助理教授。在攻读经济学之后 在哥伦比亚大学，她获得了耶鲁大学的医学博士学位。布鲁门撒尔博士完成内科 以及麻省理工学院的过敏/免疫学培训，以及哈佛大学公共学院的理学硕士学位 健康。布鲁门撒尔博士的目标是成为药物过敏流行病学和模拟研究领域的国际领先者。 导师、培训活动和环境。布鲁门撒尔博士的导师是罗谢尔·P·瓦伦斯基， 医学博士，公共卫生硕士，直到她于2021年1月离开，领导疾病控制和预防中心。Dr。 瓦伦斯基在2006-2021年由美国国立卫生研究院资助；她成功地将5名研究员转变为独立的R01- 资助研究事业。布鲁门撒尔博士目前的导师是卡洛斯·卡马戈博士，国际公认的 过敏反应专家和美国国立卫生研究院资助的流行病学家。布鲁门撒尔博士已经获得了新的技能，包括联系 以及大型数据库分析、资源利用率分析、模拟建模和成本效益 分析。布鲁门撒尔博士可获得的合作机会、智力环境和资源 都是杰出的，并为她提供了一条明确的独立道路。 研究。据报道，超过10%的美国人对青霉素(PCN)过敏，尽管自我报告的PCN 过敏反应罕见地反映出对多氯联苯和其他β-内酰胺类抗生素的耐受性。不必要地使用 β-内酰胺类替代抗生素会导致更多的抗菌素耐药性和医疗保健相关感染。 β-内酰胺类抗生素是引起药物过敏反应的最常见原因，由免疫介导 药物不良反应的子集。PCN过敏评估可以区分患有和不患有PCN的患者 真正的PCN过敏症。K01科学计划，青霉素过敏的临床和经济影响， 有三个符合国家优先事项的具体目标，包括遏制抗菌素耐药性： 1)评估已报道的PCN过敏的临床和经济影响。 2)确定β-内酰胺类抗生素的使用频率、预测因素和对医疗资源的影响。 3)预测PCN过敏评估的临床结果、预算影响和成本效益。 完成这项研究提案和培训计划将使布鲁门塔尔博士能够进行独立研究 作为一名药物过敏专家，具有临床流行病学和决策科学的方法技能。